HC Wainwright Comments on GH Research FY2029 Earnings

GH Research PLC (NASDAQ:GHRS) – Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of GH Research in a report released on Monday, January 27th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings of $0.10 per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for GH Research’s current full-year earnings is ($0.79) per share.

Separately, Canaccord Genuity Group reduced their price target on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th.

GH Research Stock Performance

Shares of GH Research stock opened at $9.50 on Tuesday. The business’s 50 day moving average price is $8.41 and its 200 day moving average price is $8.92. The company has a market cap of $494.29 million, a price-to-earnings ratio of -12.03 and a beta of 0.84. GH Research has a one year low of $6.00 and a one year high of $14.99.

Institutional Investors Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the quarter. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 at the end of the most recent reporting period. Institutional investors own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).